US 2003/0199043 A1 · Albumin fusion proteins

An albumin fusion protein comprising a member selected from the group consisting of:

(a) a Therapeutic protein:X and albumin comprising the amino acid sequence of SEQ ID NO:18;
(b) a Therapeutic protein:X and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity;
(c) a Therapeutic protein:X and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity, and further wherein said albumin activity is the ability to prolong the shelf life of the Therapeutic protein:X compared to the shelf-life of the Therapeutic protein:X in an unflised state;
(d) a Therapeutic protein:X and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity, and further wherein the fragment or variant comprises the amino acid sequence of amino acids 1-387 of SEQ ID NO:18;
(e) a fragment or variant of a Therapeutic protein:X and albumin comprising the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has a biological activity of the Therapeutic protein:X;
(f) a Therapeutic protein:X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the Therapeutic protein:X, or fragment or variant thereof, is fused to the N-terminus of albumin, or the N-terminus of the fragment or variant of albumin;
(g) a Therapeutic protein:X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the Therapeutic protein:X, or fragment or variant thereof, is fused to the C-terminus of albumin, or the C-terminus of the fragment or variant of albumin;
(h) a Therapeutic protein:X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the Therapeutic protein:X, or fragment or variant thereof, is fused to the N-terminus and C-terminus of albumin, or the N-terminus and the C-terminus of the fragment or variant of albumin;
(i) a Therapeutic protein:X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), which comprises a first Therapeutic protein:X, or fragment or variant thereof, and a second Therapeutic protein:X, or fragment or variant thereof, wherein said first Therapeutic protein:X, or fragment or variant thereof, is different from said second Therapeutic protein:X, or fragment or variant thereof;
(j) a Therapeutic protein:X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (i), wherein the Therapeutic protein:X, or fragment or variant thereof, is separated from the albumin or the fragment or variant of albumin by a linker;
and
(k) a Therapeutic protein:X, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (j), wherein the albumin fusion protein has the following formula:
R1-L-R2;
R2-L-R1;
or R1-L-R2-L-R1,
and further wherein R1 is Therapeutic protein:X, or fragment or variant thereof, L is a peptide linker, and R2 is albumin comprising the amino acid sequence of SEQ ID NO:18 or a fragment or variant of albumin.

13 more elements

An albumin fusion protein comprising a member selected from the group consisting of:

(a) an interferon-alpha polypeptide and albumin comprising the amino acid sequence of SEQ ID NO:18;
(b) an interferon-alpha polypeptide and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity;
(c) an interferon-alpha polypeptide and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity, and further wherein said albumin activity is the ability to prolong the shelf life of the interferon-alpha polypeptide compared to the shelf-life of the interferon-alpha polypeptide in an unfused state;
(d) an interferon-alpha polypeptide and a fragment or a variant of the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has albumin activity, and further wherein the fragment or variant comprises the amino acid sequence of amino acids 1-387 of SEQ ID NO:18;
(e) a fragment or variant of an interferon-alpha polypeptide and albumin comprising the amino acid sequence of SEQ ID NO:18, wherein said fragment or variant has antiviral activity or inhibits cell proliferation;
(f) an interferon-alpha polypeptide, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the interferon-alpha polypeptide, or fragment or variant thereof, is fused to the N-terminus of albumin, or the N-terminus of the fragment or variant of albumin;
(g) an interferon-alpha polypeptide, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the interferon-alpha polypeptide, or fragment or variant thereof, is fused to the C-terminus of albumin, or the C-terminus of the fragment or variant of albumin;
(h) an interferon-alpha polypeptide, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), wherein the interferon-alpha polypeptide, or fragment or variant thereof, is fused to the N-terminus and C-terminus of albumin, or the N-terminus and the C-terminus of the fragment or variant of albumin;
(i) an interferon-alpha polypeptide, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (e), which comprises the interferon-alpha polypeptide, or fragment or variant thereof, and a Therapeutic protein:X, or fragment or variant thereof, wherein said interferon-alpha polypeptide, or fragment or variant thereof, is different from said second Therapeutic protein:X, or fragment or variant thereof;
(j) an interferon-alpha polypeptide, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (i), wherein the interferon-alpha polypeptide, or fragment or variant thereof, is separated from the albumin or the fragment or variant of albumin by a linker;
and
(k) an interferon-alpha polypeptide, or fragment or variant thereof, and albumin, or fragment or variant thereof, of (a) to (j), wherein the albumin fusion protein has the following formula:
R1-L-R2;
R2-L-R1;
or R1-L-R2-L-R1,
and further wherein R1 is interferon-alpha polypeptide, or fragment or variant thereof, L is a peptide linker, and R2 is albumin comprising the amino acid sequence of SEQ ID NO:18 or a fragment or variant of albumin.

13 more elements

Albumin fusion proteins

Life of this patent

Albumin fusion proteins

Life of this patent

Abstract

Claims60